Regonat 40mg Bottle Of 28 Tablets
By NATCO PHARMA LTD
28 Tablet(s) in Bottle
₹7623.00
✱
₹9900.00
23% OFF
₹272.25/tablet
(Inclusive of all taxes)
✱
Offer applicable on order above ₹1000Non ReturnableRead More
All the Products are packed and stored Safely
Description
Regonat tablet is used in the treatment of colon and rectal cancer. It contains regorafenib as its main ingredient. Regonat Tablet should be taken with food, and it is advisable to take it at the same time every day to maximise benefits.
The most common side effects of this medicine include infection, low blood platelet count, anaemia, decreased appetite, hemorrhage, and high blood pressure. If any of these side effects trouble you, inform your doctor.
Regular blood tests are necessary to monitor your blood cells and liver function. Many other medications can interact with this medicine, so be sure to inform your healthcare team about all the medications you are taking.
This medicine is not recommended during pregnancy or while breastfeeding. Effective contraception for both males and females is important during treatment to prevent pregnancy.
Product Summary
| Offer Price | ₹7623.00 |
| You Save | ₹2277.00 (23% on MRP) |
| Contains | Regorafenib(40.0 Mg) |
| Uses | Cancer of colon and rectum |
| Side effects | Low blood platelets, anemia, decreased appetite, hemorrhage, and high blood pressure |
| Therapy | ANTI-NEOPLASTIC |
Uses
Regonat tablet is used in the treatment of colon and rectal cancer.
Contraindications
Allergy to Regorafenib or to any of the excipients of this medicine.
Side effects
- Diarrhoea
- Stomatitis
- Vomiting
- Nausea
- Constipation
- Thrombocytopenia
- Anaemia
- Decreased appetite and food intake
- Haemorrhage
- Hypertension
- Dysphonia
- Hyperbilirubinaemia
- Increase in transaminases
- Rash
- Weight loss
Precautions and Warnings
Pregnancy
Q:
Can I take Retgonat tablet during pregnancy?
A:
Retgonat tablet may cause fetal harm. Women of childbearing potential and men should ensure effective contraception during treatment and for up to 8 weeks after therapy completion.
Breast Feeding
Q:
Can I take Regonat tablet while breastfeeding?
A:
Breastfeeding must be discontinued during treatment with Regonat ablet.
Driving
Q:
Can I drive if I have consumed Regonat tablet?
A:
If you experience symptoms affecting your ability to concentrate and react during treatment with the Regonat tablet, it is recommended that you do not drive or use machines until the effect subsides.
Other General Warnings
Talk to your doctor if
- You have liver disease or a history of liver problems.
- You have a history of Gilbert's syndrome.
- You have an active infection or develop signs of an infection that worsen.
- You have a condition that predisposes you to bleeding.
- You are taking blood thinners (anticoagulants) like warfarin or phenprocoumon.
- You have liver cirrhosis.
- You develop severe abdominal pain.
- You have unstable angina, new-onset angina (within the last 3 months), or a recent heart attack (within the last 6 months).
- You have heart failure (NYHA Class 2 or higher).
- You have a history of ischemic heart disease and experience new or worsening chest pain or other signs of reduced blood flow to the heart.
- You experience seizures, severe headaches, altered mental status, vision changes, or cortical blindness, possibly with high blood pressure.
- You have high blood pressure that is not well controlled.
- You have risk factors for aneurysms or artery dissections, such as high blood pressure or a history of aneurysm.
- You develop signs of Thrombotic Microangiopathy (TMA) such as fatigue, fever, confusion, decreased urination, or bruising easily.
- You are scheduled for major surgery.
- You develop a severe or persistent skin rash, especially on your hands and feet (Hand-Foot Skin Reaction).
- You experience persistent or recurrent significant changes in your blood electrolyte levels (e.g., low phosphate, calcium, sodium, or potassium).
- You experience persistent or recurrent significant changes in thyroid-stimulating hormone, lipase, or amylase levels.
- You are on a low-sodium diet.
- You have a known allergy to soya or lecithin derived from soya.
Directions for Use
Regonat tablet should be taken with food, and it is advisable to take it at the same time every day to maximise benefits.
Storage and disposal
Store in the original package in order to protect from moisture.
Dosage
Overdose
Please seek immediate medical care in case of overdose.
Missed a Dose
If a dose is missed, it should be taken on the same day as soon as the patient remembers. The patient should not take two doses on the same day to compensate for a missed dose. In case of vomiting after Regonat tablet administration, the patient should not take additional tablets....
Mode of Action
How Does It Work?
Regorafenib acts as a multi-kinase inhibitor, effectively blocking key proteins involved in tumor growth, blood vessel formation, spread, and interaction with the immune system. By targeting VEGFR, KIT, RET, RAF, BRAF, PDGFR, FGFR, TIE2, and CSF1R, it disrupts multiple pathways critical for cancer cell survival and progression simultaneously. This broad inhibition, combined with the activity of its major metabolites, contributes to the anti-tumor effects observed in various cancer models....
Interactions
Interactions with other medicines
- CYP3A4 Inhibitors: Strong inhibitors (e.g., ketoconazole, clarithromycin, grapefruit juice) can increase regorafenib exposure and decrease active metabolite exposure. Avoid concomitant use.
- UGT1A9 Inhibitors: Strong inhibitors (e.g., mefenamic acid, diflunisal) should be avoided due to potential unknown effects on regorafenib and metabolite levels.
- CYP3A4 Inducers: Strong inducers (e.g., rifampicin, phenytoin, St. John's Wort) can decrease regorafenib exposure and increase one active metabolite. Avoid or consider alternative medications.
- UGT1A1/9 Substrates: Regorafenib can increase the exposure of drugs metabolized by these enzymes (e.g., irinotecan's active metabolite SN-38).
- BCRP Substrates: Regorafenib can significantly increase the plasma concentrations of BCRP substrates (e.g., rosuvastatin, methotrexate). Monitor for increased side effects.
- P-glycoprotein Substrates: No clinically significant interaction observed with digoxin.
- P-glycoprotein and BCRP Inhibitors/Inducers: May affect the exposure of regorafenib's active metabolites (M-2 and M-5); clinical significance is unknown.
- CYP2C8, CYP2C9, CYP2B6, CYP3A4, CYP2C19 Substrates: No clinically meaningful drug interaction expected.
- Antibiotics (Neomycin): Can significantly decrease the exposure of active metabolites M-2 and M-5, potentially reducing regorafenib efficacy.
- Bile Salt-Sequestering Agents: May decrease regorafenib absorption, potentially reducing efficacy.
Content Details
WRITTEN BY
Ravindra Ghongade
B. Pharm
REVIEWED BY
Dr. Nikita Toshi
BDS (Bachelor of Dental Surgery), WHO FIDES member
Did you find this medicine information helpful?
Please rate your experience
Product Details
Brand
REGONAT
Country of Origin
India
Expiry Date
15/10/2025
Manufacturer Details
Blog Articles
Chronic Condition Articles
Disclaimer
The information provided herein is supplied to the best of our abilities to make it accurate and reliable as it is published after a review by a team of professionals. This information is solely intended to provide a general overview on the product and must be used for informational purposes only. You should not use the information provided herein to diagnose, prevent, or cure a health problem. Nothing contained on this page is intended to create a doctor-patient relationship, replace or be a substitute for a registered medical practitioner's medical treatment/advice or consultation. The absence of any information or warning to any medicine shall not be considered and assumed as an implied assurance. We highly recommend that you consult your registered medical practitioner for all queries or doubts related to your medical condition. You hereby agree that you shall not make any health or medical-related decision based in whole or in part on anything contained in the Site. Please click here for detailed T&C.
Please add item(s) to proceed
